Presented by Jean Chastre, France

Ventilator-associated pneumonia is one of the most common infections occurring in mechanically ventilated patients and is frequently caused by antibiotic-resistant bacteria. Persistently high mortalities for pneumonia in the intensive care unit argue for a continued reassessment of our current modalities of diagnosis and therapy, as well as definition of better protocols. More active antibacterial agents are still needed, especially for problematic pathogens that are now emerging in many countries worldwide, such as multidrug-resistant nonfermenting gram-negative bacilli and ESBL-producing Enterobacteriaceae (including carbapenemase-producing Gram-negative bacilli), as well as a better use of already available antimicrobial agents based on optimised PK/PD parameters.

This webinar reviewed important aspects of this dreadful disease and provide guidance on the most effective diagnostic, treatments and management strategies for adult patients with HAP and VAP.

Supported by